These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27055778)

  • 1. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
    Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
    Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
    Miyazaki Y; Niino M; Fukazawa T; Takahashi E; Nonaka T; Amino I; Tashiro J; Minami N; Fujiki N; Doi S; Kikuchi S
    Clin Immunol; 2014 Apr; 151(2):127-35. PubMed ID: 24607506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
    Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
    PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
    Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
    Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
    Blumenfeld-Kan S; Staun-Ram E; Miller A
    Mult Scler Relat Disord; 2019 Sep; 34():29-37. PubMed ID: 31228713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
    Miyazaki Y; Niino M; Takahashi E; Suzuki M; Mizuno M; Hisahara S; Fukazawa T; Amino I; Nakano F; Nakamura M; Akimoto S; Minami N; Fujiki N; Doi S; Shimohama S; Terayama Y; Kikuchi S
    Clin Immunol; 2018 Feb; 187():95-101. PubMed ID: 29079163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
    CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis.
    Smets I; Prezzemolo T; Imbrechts M; Mallants K; Mitera T; Humblet-Baron S; Dubois B; Matthys P; Liston A; Goris A
    Front Immunol; 2021; 12():676619. PubMed ID: 34122439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
    Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
    Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
    Muls N; Dang HA; Sindic CJ; van Pesch V
    PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.
    Piancone F; Saresella M; Marventano I; La Rosa F; Zoppis M; Agostini S; Longhi R; Caputo D; Mendozzi L; Rovaris M; Clerici M
    Sci Rep; 2016 Jul; 6():29699. PubMed ID: 27412504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.
    Duddy M; Niino M; Adatia F; Hebert S; Freedman M; Atkins H; Kim HJ; Bar-Or A
    J Immunol; 2007 May; 178(10):6092-9. PubMed ID: 17475834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
    J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.
    Thomas K; Sehr T; Proschmann U; Rodriguez-Leal FA; Haase R; Ziemssen T
    J Neuroinflammation; 2017 Feb; 14(1):41. PubMed ID: 28231856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis.
    Sic H; Kraus H; Madl J; Flittner KA; von Münchow AL; Pieper K; Rizzi M; Kienzler AK; Ayata K; Rauer S; Kleuser B; Salzer U; Burger M; Zirlik K; Lougaris V; Plebani A; Römer W; Loeffler C; Scaramuzza S; Villa A; Noguchi E; Grimbacher B; Eibel H
    J Allergy Clin Immunol; 2014 Aug; 134(2):420-8. PubMed ID: 24679343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.